Antinuclear antibody (ANA) testing by indirect immunofluorescence assay (IFA) on HEp-2 cells remains the gold standard screening method for systemic autoimmune rheumatic diseases (SARD), including systemic lupus erythematosus, systemic sclerosis and Sjögren’s syndrome. However, manual interpretation of ANA HEp-2 IFA patterns is time-consuming, operator-dependent and subject to inter-observer variability. A recent large-scale study published in […]

Atypical hemolytic uremic syndrome (aHUS), also known as complement-mediated thrombotic microangiopathy (CM-TMA), is a rare but life-threatening condition caused by dysregulation of the alternative complement pathway. Among the known etiologies, autoantibodies against complement factor H (anti-factor H) play a critical role, accounting for approximately 10% of cases. Accurate laboratory detection of these antibodies is essential, […]

In regions affected by recurrent cholera outbreaks, overlapping infectious diseases can obscure the diagnosis of post-infectious autoimmune conditions. We recently collaborated in the publication describing a pediatric case from Yemen that illustrates how Guillain–Barré Syndrome (GBS) can emerge during a cholera outbreak, highlighting the critical role of Campylobacter jejuni infection and anti-ganglioside antibody testing 1. […]

Discover the 2026 Product Catalog – The Latest in Autoimmune Diagnostics Medipan GmbH and GA Generic Assays GmbH proudly present the 2026 Product Catalog, showcasing our expanded portfolio of diagnostic solutions for autoimmune diseases. This edition highlights the latest innovations in immunodiagnostics and equips healthcare professionals, researchers, and laboratory partners with tools to advance diagnostics […]

Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disorders driven by immune dysregulation, environmental triggers, genetic predisposition, and alterations in the gut microbiota. Growing evidence highlights the role of serological biomarkers in IBD in improving disease characterization, early diagnostic refinement, and patient stratification. A new large-scale prospective investigation […]

Understanding Anti-GAD65 Antibodies and Their Clinical Significance Anti-glutamic acid decarboxylase antibodies (anti-GAD65) are among the most important biomarkers in autoimmune diseases. They play a dual diagnostic role: These antibodies can reach concentrations 100–500 times higher in neurological disease compared with diabetes, making quantitative accuracy crucial. A recently published scientific study evaluated the clinical performance of […]

A German Pilot Study Using AI-Assisted Interpretation of ANA Artificial intelligence is rapidly transforming medical diagnostics—from radiology to immunology. Now, a new German pilot study reveals how AI-assisted interpretation of ANA tests could lead to faster, more consistent, and more reliable diagnosis of autoimmune diseases. With this study, the University Medical Center Regensburg and Asklepios […]

Anti-neutrophil cytoplasmic antibodies (ANCA) Anti-neutrophil cytoplasmic antibodies (ANCA) are key biomarkers in the diagnosis of ANCA-associated vasculitis (AAV), a group of rare but potentially life-threatening autoimmune diseases. They can also have clinical and diagnostic value in certain non-AAV conditions. Early and accurate detection of ANCA is critical for initiating treatment promptly and improving long-term outcomes. […]

We are pleased to share the results of a newly published peer-reviewed study in Scientific Reports that demonstrates the diagnostic performance of the CytoBead® ANA 2 assay1. In clinical diagnostics, the detection of antinuclear antibodies (ANA) is crucial in identifying systemic autoimmune rheumatic diseases (SARDs). Traditional diagnostics use a two-step process. First, ANA screening by […]

Type 1 diabetes management has long relied on insulin injections, carbohydrate counting, and vigilant blood sugar monitoring. But how will the landscape in the near future look like? According to prominent German pediatric endocrinologist Felix Reschke (Kinder- und Jugendkrankenhaus in Hannover), the next five years could redefine treatment strategies entirely – he said in an […]